NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01358877,A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer,https://clinicaltrials.gov/study/NCT01358877,APHINITY,COMPLETED,"This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).",YES,Breast Cancer,DRUG: 5-Fluorouracil|DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Paclitaxel|DRUG: Pertuzumab|DRUG: Placebo|DRUG: Trastuzumab,"Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings, Percentage of participants with IDFS events (excluding SPNBC) is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (that is \[i.e.\], an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including ductal carcinoma in situ \[DCIS\] and lobular carcinoma in situ \[LCIS\]) and non-melanoma skin cancer were excluded as an event., Randomization to the first occurrence of IDFS event (excluding SPNBC) (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months)|Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at Year 3, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings, Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (excluding SPNBC) at Year 3 is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event., 3 years","Percentage of Participants With IDFS Event (Including SPNBC), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings, Percentage of participants with IDFS events (including SPNBC) is reported. IDFS-SPNBC event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site)., Randomization to the first occurrence of IDFS event (including SPNBC) (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months)|Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at Year 3, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings, Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (including SPNBC) at Year 3 is reported. IDFS-SPNBC was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site)., 3 years|Percentage of Participants With Disease-Free Survival (DFS) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings, Percentage of participants with DFS event is reported. DFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS., Randomization to the first occurrence of DFS event (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months)|Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at Year 3, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings, Kaplan-Meier estimate of the percentage of participants who were DFS event-free at Year 3 is reported. DFS was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS., 3 years|Percentage of Participants Who Died, Percentage of participants who died due to any cause is reported., Randomization until death due to any cause (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months)|Kaplan-Meier Estimate of the Percentage of Participants Who Were Alive at Year 3, The Kaplan-Meier approach was used to estimate the percentage of participants who were alive at 3 years., 3 years|Percentage of Participants With Recurrence-Free Interval (RFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings, Percentage of participants with RFI event is reported. RFI event was defined as local, regional or distant breast cancer recurrence., Randomization until local, regional or distant breast cancer recurrence (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months)|Kaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at Year 3, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings, Kaplan-Meier estimate of the percentage of participants who were RFI event-free at Year 3 is reported. RFI event was defined as local, regional or distant breast cancer recurrence., 3 years|Percentage of Participants With Distant Recurrence-Free Interval (DRFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings, Percentage of participants with DRFI event is reported. DRFI event was defined as distant breast cancer recurrence., Randomization until distant breast cancer recurrence (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months)|Kaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at Year 3, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings, Kaplan-Meier estimate of the percentage of participants who were DRFI event-free at Year 3 is reported. DRFI event was defined as distant breast cancer recurrence., 3 years|Percentage of Participants With Primary Cardiac Event, Primary cardiac event was defined as either: Heart Failure (New York Heart Association \[NYHA\] Class III or IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction (EF) points from baseline and to below 50 percent (%); or cardiac death. Cardiac death was defined as either definite cardiac death: due to heart failure, myocardial infarction, or documented primary arrhythmia; or probable cardiac death: sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology., Baseline until data cut-off date 19 December 2016 (up to maximum length of follow-up of 59 months)|Percentage of Participants With Secondary Cardiac Event, Secondary cardiac event was defined as asymptomatic or mildly symptomatic (NYHA Class II) significant drop in LVEF (defined as an absolute decrease of at least 10 EF points from baseline and to below 50%), confirmed by a second LVEF assessment within approximately three weeks of the first significant LVEF assessment or confirmed by the Cardiac Advisory Board (CAB)., Baseline until data cut-off date 19 December 2016 (up to maximum length of follow-up of 59 months)|Change From Baseline in LVEF to Worst Post-Baseline Value, LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. Baseline LVEF value and the maximum absolute decrease (worst value) in LVEF measurement from baseline were reported. LVEF was measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan., Baseline until data cut-off date 19 December 2016 (up to maximum length of follow-up of 59 months)|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Scale Score, EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall quality of life (QOL) in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, used 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 global scores were linearly transformed on a scale of 0 to 100, with a high score indicating better GHS/QOL. Negative change from Baseline values indicated deterioration in QOL or functioning and positive values indicated improvement., Baseline, Weeks 13, 25; end of treatment (EOT, 28 days after the last dose, up to Week 56); Follow-up (FU) Months 18, 24, 36|Change From Baseline in EORTC QLQ-C30 Functioning Subscale Scores, EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 functioning scores were linearly transformed on a scale of 0 to 100, with a high score indicating better functioning/support. Negative change from Baseline values indicated deterioration in functioning and positive values indicated improvement., Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36|Change From Baseline in EORTC QLQ-C30 Disease/Treatment-Related Symptoms Subscale Scores, EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 disease/treatment-related symptom scores were linearly transformed on a scale of 0 to 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicated improvement in symptoms and positive values indicated worsening of symptoms., Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36|Change From Baseline in EORTC QLQ-C30 Financial Difficulties Subscale Scores, EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 financial difficulties scores were linearly transformed on a scale of 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicated improvement in financial difficulties and positive values indicated worsening of financial difficulties., Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36|Change From Baseline in European Organisation for Research and Treatment of Cancer - Breast Cancer Module Quality of Life (EORTC QLQ-BR23) Functional Scale Score, EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL., Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36|Change From Baseline in EORTC QLQ-BR23 Symptom Scale Score, EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for symptom scale indicated high level of symptomatology/problems/greater degree of symptoms. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL., Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36|Percentage of Participants With Response for European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Mobility Domain, EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in mobility domain was reported: I have no problems in walking about; I have some problems in walking about; and I am confined to bed. Response percentages may not add up to 100% due to data rounding., Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36|Percentage of Participants With Response for EQ-5D-3L Questionnaire: Self-Care Domain, EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in self-care domain was reported: I have no problems with self-care; I have some problems washing or dressing myself; and I am unable to wash or dress myself. Response percentages may not add up to 100% due to data rounding., Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36|Percentage of Participants With Response for EQ-5D-3L Questionnaire: Usual Activities Domain, EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in usual activities domain was reported: I have no problems with performing my usual activities; I have some problems with performing my usual activities; and I am unable to perform my usual activities. Response percentages may not add up to 100% due to data rounding., Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36|Percentage of Participants With Response for EQ-5D-3L Questionnaire: Pain/Discomfort Domain, EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in pain/discomfort domain was reported: I have no pain or discomfort; I have moderate pain or discomfort; and I have extreme pain or discomfort. Response percentages may not add up to 100% due to data rounding., Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36|Percentage of Participants With Response for EQ-5D-3L Questionnaire: Anxiety/Depression Domain, EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in anxiety/depression domain was reported: I am not anxious or depressed; I am moderately anxious or depressed; and I am extremely anxious or depressed. Response percentages may not add up to 100% due to data rounding., Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36|Trough Serum Concentration (Cmin) of Pertuzumab, Cycles 1, 10 and 15 (Cycle length=21 days)|Cmin of Trastuzumab, Cycles 1, 10 and 15 (Cycle length=21 days)|Peak Serum Concentration (Cmax) of Pertuzumab, Cycles 1, 10 and 15 (Cycle length=21 days)|Cmax of Trastuzumab, Cycles 1, 10 and 15 (Cycle length=21 days)",,Hoffmann-La Roche,"Genentech, Inc.|Breast International Group",ALL,"ADULT, OLDER_ADULT",PHASE3,4804,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",BO25126|TOC4939G|2010-022902-41|BIG 4-11,2011-11-08,2016-12-19,2024-11-28,2011-05-24,2018-01-05,2025-03-25,"HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, 85258, United States|Providence Regional Medical Center, Everett, California, 98208, United States|Marin Cancer Care Inc, Greenbrae, California, 94904, United States|Kaiser Permanente - Hayward, Hayward, California, 94545, United States|UCSD Moores Cancer Center, La Jolla, California, 92093, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|Kaiser Permanente - Oakland, Oakland, California, 94611, United States|Kaiser Permanente - Roseville, Roseville, California, 95661, United States|Sutter Cancer Center, Sacramento, California, 95816, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, 95825, United States|Southern California Kaiser Permanente, San Diego, California, 92108, United States|K. Permanente - San Fransisco, San Francisco, California, 94115, United States|K. Permanente - San Jose, San Jose, California, 95119, United States|K. Permanente - Santa Clara, Santa Clara, California, 95051, United States|K. Permanente - S. San Fran, South San Francisco, California, 94080, United States|Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, 94589, United States|K. Permanente - Walnut Creek, Walnut Creek, California, 94596, United States|Rocky Mountain Cancer Center - Denver, Littleton, Colorado, 80120, United States|Lutheran Hematology &Oncology, Wheat Ridge, Colorado, 80033, United States|Eastern Ct Hema/Onco Assoc; Dept of Oncology, Norwich, Connecticut, 06360, United States|Washington Cancer Institute at MedStar Washington Hospital Center., Washington, District of Columbia, 20010, United States|Georgetown U; Lombardi Comp Can, Washington, District of Columbia, 20016-1468, United States|Florida Cancer Specialists; SCRI, Fort Myers, Florida, 33901, United States|Memorial Cancer Institute, Hollywood, Florida, 33021, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, 32224, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, 32256, United States|Ocala Oncology Center, Ocala, Florida, 34471, United States|Memorial Breast Cancer Center, Pembroke Pines, Florida, 33028-1006, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, 34952, United States|Florida Cancer Specialists; Saint Petersburg, Saint Petersburg, Florida, 33719, United States|Florida Cancer Specialists, Research Department, West Palm Beach, Florida, 33401, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, 31701, United States|Georgia Cancer Specialists, Atlanta, Georgia, 30341, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, 30060, United States|Kootenai Cancer Center, Post Falls, Idaho, 83854, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|Uni of Chicago, Chicago, Illinois, 60637, United States|Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States|Loyola University Med Center, Maywood, Illinois, 60153, United States|Edward Cancer Center Naperville, Naperville, Illinois, 60540, United States|Illinois Cancer Care, Peoria, Illinois, 61615, United States|Edward Cancer Center Plainfield, Plainfield, Illinois, 60585, United States|Quincy Medical Group; Canc Ctr at Blessing Hosp, Quincy, Illinois, 62301, United States|Carle Foundation, Urbana, Illinois, 61801, United States|University of Iowa, Iowa City, Iowa, 52242, United States|Cancer Center of Kansas, Wichita, Kansas, 67214-3728, United States|Cancer Center of Acadiana at Lafayette General, Lafayette, Louisiana, 70506, United States|Cancer Care of Maine, Brewer, Maine, 04412, United States|New England Cancer Specialists, Scarborough, Maine, 04074, United States|Mercy Medical Center, Baltimore, Maryland, 21202, United States|Weinberg CA Inst Franklin Sq, Baltimore, Maryland, 21237, United States|Maryland Oncology & Hematology, PA, Bethesda, Maryland, 20817, United States|Massachusetts General Hospital., Boston, Massachusetts, 02114, United States|Boston Medical Center, Boston, Massachusetts, 02118-2525, United States|Dana Farber Cancer Institute at Faulkner Hospital, Boston, Massachusetts, 02130, United States|Beth Israel Deac Med Ctr; East Campus Rsch Pharmacy, Boston, Massachusetts, 02215, United States|Dana Farber Can Ins, Boston, Massachusetts, 02215, United States|Berkshire Hematology, Oncology Pc, Pittsfield, Massachusetts, 01201, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, 49503, United States|West Michigan Cancer Center, Kalamazoo, Michigan, 49007, United States|Southdale Cancer Clinic, Edina, Minnesota, 55414, United States|Coborn Cancer Center, Saint Cloud, Minnesota, 56303, United States|Metro-Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, 55416, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, 39202, United States|University of Missouri-Columbia; Ellis Fischel Cancer Center, Kansas City, Missouri, 64108, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Heartland CCOP/Missouri Baptist Medical Center, Saint Louis, Missouri, 63131, United States|Cancer Alliance of Nebraska, Lincoln, Nebraska, 68510, United States|Cancer Alliance of Nebraska, Omaha, Nebraska, 68106, United States|Dartmouth Hitchcock Med Center, Lebanon, New Hampshire, 03756, United States|Saint Barnabas Medical Center, Livingston, New Jersey, 07039, United States|New York Oncology Hematology, P.C., Albany, New York, 12206, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|Roswell Park Cancer Inst., Buffalo, New York, 14263, United States|Mount Sinai Beth Israel Medical Center, New York, New York, 10003, United States|Mount Sinai Beth Israel Comprehensive Cancer Center, New York, New York, 10011, United States|Mount Sinai West, New York, New York, 10019, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, 27599, United States|Carolina Oncology Specialists, PA - Hickory, Hickory, North Carolina, 28602, United States|Dayton Clinical Oncology Prog, Centerville, Ohio, 45459, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, 45242, United States|The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, 43219, United States|Toledo Clinic Cancer Center, Toledo, Ohio, 43623-3536, United States|Northwest Cancer Specialists - Portland (NE Hoyt St), Portland, Oregon, 97213, United States|Abramson Cancer Center; Univ of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Albert Einstein Healthcare Network ; Cancer Center, Philadelphia, Pennsylvania, 19141, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, 15213, United States|Charleston Oncology, P .A, Charleston, South Carolina, 29414, United States|Roper Bon Secours St. Francis Cancer Center, Charleston, South Carolina, 29414, United States|South Carolina Oncology Associates - SCRI, Columbia, South Carolina, 29210, United States|Cancer Centers of the Carolina; Eastside Medical Center, Greenville, South Carolina, 29615, United States|Sanford USD School of Medicine, Sioux Falls, South Dakota, 57104, United States|Tennessee Oncology , PLLC - Chattanooga, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology - Nashville, Nashville, Tennessee, 37203, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, 37204, United States|Texas Oncology-Medical City Dallas, Dallas, Texas, 75230, United States|Texas Oncology - DFW at Dallas Presbyterian Hospital, Dallas, Texas, 75231, United States|Texas Oncology - DFW, Dallas, Texas, 75246, United States|Texas Oncology-El Paso Cancer Treatment Center Grandview, El Paso, Texas, 79902, United States|Texas Oncology - DFW Fort Worth, Fort Worth, Texas, 76104, United States|The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, 76104, United States|Texas Oncology, P.A. - Garland, Garland, Texas, 77060, United States|Texas Oncology - Houston (Gessner), Houston, Texas, 77024, United States|Texas Oncology-Tyler, Irving, Texas, 75063, United States|Cancer Care Centers of South Texas-HOAST - San Antonio, New Braunfels, Texas, 78130, United States|Texas Oncology - DFW Plano, Plano, Texas, 75075, United States|Community Cancer Trials of Utah, Ogden, Utah, 84405, United States|Wellmonth Physician Services, Bristol, Virginia, 24201, United States|Virginia Cancer Institute, Richmond, Virginia, 23229, United States|Providence St. Mary Regional Cancer Center, Walla Walla, Washington, 99362, United States|West Virginia University Hospitals Inc, Morgantown, West Virginia, 26056, United States|Green Bay Oncology/St. Mary?s Hospital, Green Bay, Wisconsin, 54301, United States|Marshfield Clinic, Marshfield, Wisconsin, 54449, United States|Centro Medico San Roque, San Miguel de Tucuman, T4000IAK, Argentina|Isis Centro Especializado de Luces; Oncology, Santa Fe, S3000XAE, Argentina|Lismore Base Hospital; Cancer Care & Haematology Unit, Lismore, New South Wales, 2480, Australia|Mater Misericordiae Hospital; Chemotherapy Cottage, Sydney, New South Wales, 2060, Australia|Newcastle Mater Misericordiae Hospital; Oncology, Waratah, New South Wales, 2298, Australia|Westmead Hospital; Medical Oncology and Pallative Care, Westmead, New South Wales, 2145, Australia|Wesley Medical Centre; Clinic For Haematology and Oncology, Auchenflower, Queensland, 4066, Australia|Mater Hospital; Oncology, Brisbane, Queensland, 4101, Australia|Royal Adelaide Hospital; Oncology, Adelaide, South Australia, 5000, Australia|Royal Hobart Hospital; Medical Oncology, Hobart, Tasmania, 7000, Australia|Monash Medical Centre; Oncology, Clayton, Victoria, 3168, Australia|Geelong Hospital; Andrew Love Cancer Centre, Geelong, Victoria, 3220, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, 3084, Australia|Peter Maccallum Cancer Institute; Medical Oncology, Melbourne, Victoria, 3000, Australia|Sir Charles Gairdner Hospital; Medical Oncology, Perth, Western Australia, 6009, Australia|Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I, Graz, 8036, Austria|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, 6020, Austria|Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1, Linz, 4010, Austria|Lhk Feldkirch; Interne Medizin Abt., Rankweil, 6830, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, 5020, Austria|A. Ö. Krankenhaus Der Barmherzigen Brüder; Interne Abt., St Veit An Der Glan, 9300, Austria|Lkh Vöcklabruck; I. Abt. Für Innere Medizin, Vöcklabruck, 4840, Austria|Klinikum Kreuzschwestern Wels; Iii. Interne Abt., Wels, 4600, Austria|Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie, Wien, 1090, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, 1090, Austria|Krankenhaus Der Stadt Wien-Hietzing; Abt. Für Gynäkologie U. Geburtshilfe, Wien, 1130, Austria|Institut Jules Bordet, Anderlecht, 1070, Belgium|GHdC Site Notre Dame, Charleroi, 6000, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, 3500, Belgium|AZ Groeninge, Kortrijk, 8500, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|CHU Sart-Tilman, Liège, 4000, Belgium|Clinique Ste-Elisabeth, Namur, 5000, Belgium|Sint Augustinus Wilrijk, Wilrijk, 2610, Belgium|UMHAT Tsaritsa Yoanna - ISUL; Clinic of Oncotherapy, Sofia, 1527, Bulgaria|SHATO - Sofia, Sofia, 1756, Bulgaria|SHATOD Dr. Marko Antonov Markov-Varna, EOOD, Varna, 9010, Bulgaria|Tom Baker Cancer Centre; Dept of Medicine, Calgary, Alberta, T2N 4N2, Canada|Cross Can Inst, Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer Agency, CSI, Kelowna, British Columbia, V1Y 5L3, Canada|BC Cancer ? Surrey, Surrey, British Columbia, V3V 1Z2, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|Bcca - Vancouver Island Cancer Centre; Oncology, Victoria, British Columbia, V8R 6V5, Canada|CancerCare Manitoba; Neuro-Oncology, Winnipeg, Manitoba, R2H 2A6, Canada|Atlantic Health Science Corporation; Saint John Regional Hospital Facility, Saint John, New Brunswick, E2L 4L2, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, B3H 2Y9, Canada|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|Cancer Centre of Southeastern Ontario; Kingston General Hospital, Kingston, Ontario, K7L 5P9, Canada|London Health Sciences Centre, London, Ontario, N6A 4L6, Canada|Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre, Mississauga, Ontario, L5M 2N1, Canada|Southlake Regional Health Center, Newmarket, Ontario, L3Y 2R2, Canada|Ottawa Regional Cancer Centre, Ottawa, Ontario, K1H 1C4, Canada|Niagara Health Systems - St. Catherines General Site; Niagara Health System-St. Catharines Site, St. Catharines, Ontario, L2R 7C6, Canada|Northeastern Ontario; Regional Cancer Centre, Sudbury, Ontario, P3E 5J1, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, M4N 3M5, Canada|Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada|Princess Margaret Cancer Center, Toronto, Ontario, M5G 1Z5, Canada|Hopital Maisonneuve- Rosemont; Oncology, Montreal, Quebec, H1T 2M4, Canada|Chum Hopital Notre Dame; Centre D'Oncologie, Montreal, Quebec, H2L 4M1, Canada|Hopital Sacre-Coeur Research Centre, Montreal, Quebec, H4J 1C5, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, G1S 4L8, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada|INTOP, Providencia, 7501089, Chile|Fundacion Arturo Lopez Perez, Santiago, 7500921, Chile|Cancer Hospital Chinese Academy of Medical Sciences., Beijing, 100021, China|The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing, 100071, China|the First Hospital of Jilin University, Changchun, 130021, China|Jilin Cancer Hospital, Changchun, 132013, China|Hu Nan Provincial Cancer Hospital, Changsha, 410006, China|Sichuan Provincial People's Hospital, Chengdu, 610072, China|Fujian Medical University Union Hospital, Fuzhou City, 350001, China|The 900th Hospital of PLA joint service support force, Fuzhou, 110016, China|Sun Yet-sen University Cancer Center, Guangzhou City, 510663, China|Guangdong General Hospital, Guangzhou, 510080, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, 310003, China|Harbin Medical University Cancer Hospital, Harbin, 150081, China|The 1st Affiliated Hospital of Nanchang Unversity, Nanchang, 330019, China|Fudan University Shanghai Cancer Center, Shanghai City, 200120, China|Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital), Shanghai, 200025, China|Shanghai First People's Hospital, Shanghai, 200080, China|Changhai Hospital of Shanghai, Shanghai, 200433, China|Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province), Shijiazhuang, 050035, China|Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan, 430022, China|Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech, Wuhan, 430030, China|Hubei Cancer Hospital, Wuhan, 430079, China|Inst. Nacional de Cancerologia; Clinica de Seno, Bogota, 111511, Colombia|Fundacion Cardioinfantil, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, 050034, Colombia|Oncomedica S.A., Monteria, 230002, Colombia|Uni Hospital Split; Oncology & Radiotherapy, Split, 21000, Croatia|General Hospital Varazdin, Varazdin, 42000, Croatia|Clinical Hospital Centre Zagreb, Zagreb, 10000, Croatia|Masarykuv onkologicky ustav, Brno, 656 53, Czechia|Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, 779 00, Czechia|MULTISCAN, s.r.o., Radiologicke centrum Pardubice, Pardubice, 532 03, Czechia|Aalborg Universitetshospital; Onkologisk Afdeling, Aalborg, 9000, Denmark|Sydvestjysk Sygehus Esbjerg; Onkologisk afdeling, Esbjerg, 6700, Denmark|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, 2730, Denmark|Nordsjællands Hospital, Hillerød, Onkologisk Afdeling, Hillerod, 3400, Denmark|Rigshospitalet; Onkologisk Klinik, København Ø, 2100, Denmark|Sjællands Universitetshospital, Næstved; Onkologisk Afdeling, Naestved, 4700, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, 5000, Denmark|Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium, Roskilde, 4000, Denmark|Vejle Sygehus; Onkologisk Afdeling, Vejle, 7100, Denmark|Hospital Oncologia; Oncology, Salvador, 01101, El Salvador|Hospital Diagnostico Escalón, San Salvador, 01101, El Salvador|Clinique De L Europe; Pmsi, Amiens, 80090, France|ICO Paul Papin; Oncologie Medicale., Angers, 49055, France|HOP Prive Arras Les Bonnettes; Chimiotherapie, Arras, 62012, France|Institut Sainte Catherine, Avignon, 84082, France|ICONE, Bezannes, 51430, France|Institut Bergonie; Oncologie, Bordeaux, 33076, France|Polyclinique Bordeaux Nord, Bordeaux, 33300, France|Hopital Augustin Morvan; Federation De Cancerologie, Brest, 29200, France|Centre Francois Baclesse; Recherche Clinique, Caen, 14076, France|Centre Jean Perrin; Hopital De Jour, Clermont Ferrand, 63011, France|Centre Leonard De Vinci;Chimiotherapie, Dechy, 59187, France|Centre Georges-François Lecler; Ctr de Lutte Contre le Canc, Dijon, 21034, France|Institut Daniel Hollard, Grenoble, 38000, France|Centre Hospitalier Departemental Les Oudairies, La Roche Sur Yon, 85925, France|Clinique des Ormeaux; Oncologie, Le Havre, 76600, France|Centre Oscar Lambret; Cancerologie Gynecologique, Lille, 59020, France|Hopital Dupuytren; Oncologie Medicale, Limoges, 87042, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, 69373, France|Institut Paoli Calmettes; Oncologie Medicale, Marseille, 13273, France|Institut régional du Cancer Montpellier, Montpellier, 34298, France|Polyclinique De Gentilly; Hemodialyse, Nancy, 54100, France|Centre Antoine Lacassagne; Hopital De Jour A2, Nice, 06189, France|Institut de cancerologie du Gard, Nimes, 30029, France|Institut Curie; Oncologie Medicale, Paris, 75231, France|Ch Pitie Salpetriere; Cmrr Ile De France Salpetriere, Paris, 75651, France|Polyclinique Francheville; MED CHIMIOTHERAPIE RADIOTHERAPIE, Perigueux, 24000, France|Clinique Armoricaine Radiologie; Hopital de Jour, Plerin, 22190, France|Chu De Poitiers; Chu La Miletrie, Poitiers, 86021, France|Institut Jean Godinot; Hopital De Jour, Reims, 51056, France|Centre Eugene Marquis; Unite Huguenin, Rennes, 35042, France|Centre Henri Becquerel; Oncologie Medicale, Rouen, 76038, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, 44805, France|ICL; Hematologie, Saint-Priest en Jarez, 42271, France|Centre Rene Huguenin; CONSULT SPECIALISEES, St Cloud, 92210, France|Institut d'oncologie de l'Orangerie; Chimiotherapie, Strasbourg, 67010, France|Hopital Hautepierre; Hematologie Oncologie, Strasbourg, 67098, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, 31059, France|Clinique Pasteur; Pneumologie, Toulouse, 31076, France|Centre Alexis Vautrin; Oncologie Medicale, Vandoeuvre-les-nancy, 54519, France|Institut Gustave Roussy; Oncologie Medicale, Villejuif, 94800, France|Gesundheitszentrum St. Marien GmbH; Med. II, Hämatologie/Onkologie, Amberg, 92224, Germany|Hochwaldkrankenhaus, Bad Nauheim, 61231, Germany|Evang. Krankenhaus Frauenklinik, Bergisch Gladbach, 51465, Germany|Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare), Berlin, 10367, Germany|Praxis Dr. Schoenegg, Berlin, 10719, Germany|HELIOS Klinikum Berlin-Buch; Klinik für Gynäkologie und Geburtshilfe, Berlin, 13125, Germany|Frauenarzt-Zentrum Zehlendorf an der Teltower Eiche, Berlin, 14169, Germany|Onkologische Schwerpunktpraxis Bielefeld; Haemotologie & Internistische onkologie, Bielefeld, 33604, Germany|Universitätsklinikum Bonn; Zentrum für Geburtshilfe und Frauenheilkunde, Bonn, 53127, Germany|Praxis Dr. Ralf Lorenz, Braunschweig, 38100, Germany|Hämato-Onkologie im Medicum/Home, Bremen, 28209, Germany|Klinikum Sindelfingen-Böblingen; Frauenklinik, Böblingen, 71032, Germany|Klinikum Chemnitz gGmbH; Frauen- und Kinderklinik, Chemnitz, 09116, Germany|DONAU ISAR Klinikum Deggendorf; Frauenklinik, Deggendorf, 94469, Germany|St. Johannes-Hospital, Dortmund, 44137, Germany|Universitätsklinikum ""Carl Gustav Carus""; Frauenheilkunde und Geburtshilfe, Dresden, 01307, Germany|Universitätsklinikum Düsseldorf; Frauenklinik, Düsseldorf, 40225, Germany|Luisenkrankenhaus GmbH & Co. KG., Brustzentrum, Düsseldorf, 40235, Germany|Praxis für Hamatologie und Onkologie, Erfurt, 99085, Germany|Universitätsklinikum Erlangen; Frauenklinik, Erlangen, 91054, Germany|Klinikum Esslingen; Klinik für Frauenheilkunde und Geburtshilfe, Esslingen, 73730, Germany|Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt am Main, 60389, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik für Frauenheilkunde und Geburtshilfe, Frankfurt, 60596, Germany|Städtische Kliniken Frankfurt am Main Höchst, Frankfurt, 65929, Germany|Praxis für Interdisziplinäre Onkologie und Hämatologie GbR, Freiburg, 79110, Germany|Dres.Jochen Wilke und Harald Wagner, Fürth, 90766, Germany|Universitätsklinikum Greifswald; Klinik für Frauenheilkunde und Brustzentrum, Greifswald, 17475, Germany|Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie, Halle, 06120, Germany|Universitätsklinikum Hamburg-Eppendorf; Frauenklinik, Hamburg, 20246, Germany|SANA Klinikum Hameln-Pyrmont; Frauenklinik / Brustzentrum, Hameln, 31785, Germany|Diakovere Henriettenstift, Frauenklinik, Hannover, 30171, Germany|MVZ Onko Medical GmbH Hannover, Ralf Lohse (Geschäftsführer), Hannover, 30177, Germany|Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, 69120, Germany|Praxisgemeinschaft; Frauenärzte am Bahnhofsplatz, Hildesheim, 31134, Germany|Universitätsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe, Homburg/Saar, 66424, Germany|ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG; Frauenklinik, Karlsruhe, 76135, Germany|Elisabeth-Krankenhaus Brustzentrum, Kassel, 34117, Germany|Klinikum Kassel GmbH; Klinik für Frauenheilkunde und Geburtshilfe, Kassel, 34125, Germany|UNI-Klinikum Campus Kiel Klinik für Gynäkologie und Geburtshilfe, Kiel, 24105, Germany|St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe, Koeln, 50935, Germany|Uniklinik Köln, Klinik und Poliklinik und Geburtshilfe; Brustzentrum Köln, Köln, 50931, Germany|Klinikum Landshut Frauenklinik, Landshut, 84034, Germany|Sankt Elisabeth Krankenhaus; Gynaekology, Leipzig, 04277, Germany|Evangelisches Krankenhaus; Abt. Gynäkologie und Geburtshilfe, Ludwigsfelde, 14974, Germany|Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, 23538, Germany|Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde, Mainz, 55131, Germany|Rotkreuzklinikum München; Frauenklinik, Muenchen, 80637, Germany|Brustzentrum Rhein-Ruhr Servicegesellschaft mbH, Mönchengladbach, 41061, Germany|Klinikum der Universität München; Frauenklinik - Onkologie II, München, 80336, Germany|Klinikum rechts der Isar der TU München; Klinik und Poliklinik für Frauenheilkunde, München, 81675, Germany|Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe, Münster, 48149, Germany|Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe, Offenbach, 63069, Germany|Medizinisches Versorgungszentrum am Klinikum Oldenburg GmbH, Oldenburg, 26133, Germany|Hämatologisch/Onkologische Praxis Prof. Dr. Decker, Studienzentrum, Ravensburg, 88212, Germany|Oncologianova GmbH, Recklinghausen, 45659, Germany|RoMed Klinikum Rosenheim; Klinik für Gynäkologie und Geburtshilfe, Rosenheim, 83022, Germany|Universitätsfrauen- und Poliklinik am Klinikum Suedstadt, Rostock, 18059, Germany|MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken, Stade, 21680, Germany|Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie, Trier, 54290, Germany|Universitätsklinik Tübingen; Frauenklinik, Tübingen, 72076, Germany|Universitätsklinikum Ulm Am Michelsberg; Frauenklinik, Ulm, 89075, Germany|Dres. Arnd Nusch Naser Ali-Mohammad Kalhori und Werner Langer, Velbert, 42551, Germany|Schwarzwald-Baar Klinikum Klinik für Frauenheilkunde und Geburtshilfe, Villingen-Schwenningen, 78052, Germany|St. Josefs-Hospital Wiesbaden, Wiesbaden, 65189, Germany|Marien-Hospital Witten; Frauenklinik Brustzentrum, Witten, 58452, Germany|Hämatologisch-Onkologische Schwerpunktpraxis Dres. Schlag & Schöttker, Würzburg, 97080, Germany|Grupo Angeles, Guatemala City, 01015, Guatemala|Centro Oncológico Sixtino / Centro Oncológico SA, Guatemala, 01010, Guatemala|Queen Mary Hospital; Surgery, Hong Kong, 852, Hong Kong|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Semmelweis Egyetem Onkologiai Központ, Budapest, 1083, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, 1122, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont; Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, H-1077, Hungary|Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika, Debrecen, 4032, Hungary|Petz Aladar Megyei Oktato Korhaz; Oncoradiologia, Gyor, 9024, Hungary|Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek, Gyula, 5703, Hungary|Bács-Kiskun Vármegyei Oktatókórház, Kecskemet, 6000, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, 6720, Hungary|Veszprem Megyei Csolnoky; Ferenc Korhaz, Veszprem, 8200, Hungary|Cork Uni Hospital; Oncology Dept, Cork, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, 7, Ireland|Beaumont Hospital; Cancer Clinical Trials Unit, Dublin, 9, Ireland|St Vincent'S Uni Hospital; Medical Oncology, Dublin, D04 T6F4, Ireland|St. James Hospital; Oncology, Dublin, D08 HNY1, Ireland|Galway University Hospital; Clinical Trials Department, Galway, H91YR71, Ireland|University Hospital Limerick - Oncology, Limerick, Ireland|Rambam Medical Center; Oncology, Haifa, 3109601, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, 4941492, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, 5262100, Israel|Kaplan Medical Center; Oncology Inst., Rehovot, 7610001, Israel|Sourasky / Ichilov Hospital; Oncology Department, Tel Aviv, 64239-06, Israel|Campus Universitario S.Venuta; Centro Oncologico T.Campanella, Catanzaro, Calabria, 88100, Italy|AORN'S.G.Moscati; Oncologia, Avellino, Campania, 83100, Italy|IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A, Napoli, Campania, 80131, Italy|Ist. Uni Federico Ii; Divisione Di Oncologia Medica - Dpt. Di Medicina Interna, Napoli, Campania, 80131, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, 40138, Italy|Ospedale Ramazzini, Carpi, Emilia-Romagna, 41012, Italy|Arcispedale Santa Maria Nuova; Oncologia, Reggio Emilia, Emilia-Romagna, 42100, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, 33081, Italy|Divisione Onc Med dell'Azienda, Udine, Friuli-Venezia Giulia, 33100, Italy|Ospedale Belcolle Di Viterbo; Oncologia, Viterbo, Lazio, 01100, Italy|Ente Ospedaliero Ospedali Galliera; S.C. Oncologia Medica, Genova, Liguria, 16128, Italy|Az. Osp. Uni Ria San Martino; Cliniche Uni Rie Convenzionate U.O. Oncologia Medical, Genova, Liguria, 16132, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, 16132, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, 25123, Italy|ASST DI LECCO; Oncologia Medica, Lecco, Lombardia, 23900, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica, Milano, Lombardia, 20141, Italy|Policlinico di Monza; Istituto di Oncologia, Monza, Lombardia, 20052, Italy|IRCCS Fondazione Maugeri; Oncologia Medica I, Pavia, Lombardia, 27100, Italy|IRCCS Istituto Clinico Humanitas; Oncologia, Rozzano (MI), Lombardia, 20089, Italy|Az. Osp. Di Busto P.O. Di Saronno; U.O. Di Oncologia Medica, Saronno, Lombardia, 21047, Italy|Ospedale S. Croce Di Fano; Servizio Oncologia, Fano, Marche, 61032, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, 10060, Italy|Ospedale Antonio Perrino; Oncologia Medica, Brindisi, Puglia, 72100, Italy|Nuovo Ospedale di Prato S. Stefano - Azienda USL Toscana Centro, Prato, Toscana, 59100, Italy|Ospedale Di Bolzano; Dept. Di Oncologia, Bolzano, Trentino-Alto Adige, 39100, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, 06156, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, 05100, Italy|Ospedale Mater Salutis; Dept of Oncology, Legnago, Veneto, 37045, Italy|Aichi Cancer Center Hospital, Breast Oncology, Aichi, 464-8681, Japan|Chiba Cancer Center; Breast Surgical Oncology, Chiba, 260-8717, Japan|National Cancer Center Hospital East, Chiba, 277-8577, Japan|Natl Hosp Org Shikoku; Cancer Ctr, Surgery, Ehime, 791-0280, Japan|National Hospital Organization Kyushu Cancer Center;Breast Oncology, Fukuoka, 811-1395, Japan|Gunma University Hospital; Department of Thoracic and Visceral Organ Surgery, Gunma, 371-8511, Japan|Hiroshima City Hiroshima Citizens Hospital; Breast Surgery, Hiroshima, 730-8518, Japan|Iwate Med Univ School of Med; Surgery, Iwate, 028-3695, Japan|Sagara Hospital; Breast Surgery, Kagoshima, 892-0833, Japan|St. Marianna University School of Medicine Hospital, Breast and Endocrine Surgery, Kanagawa, 216-8511, Japan|Tokai University Hospital, Breast Surgery, Kanagawa, 259-1193, Japan|Kumamoto City Hospital, Breast and Endocrine Surgery, Kumamoto, 862-8505, Japan|Kumamoto Shinto General Hospital; Breast Cancer Center, Kumamoto, 862-8655, Japan|Kyoto University Hospital; Breast Surgery, Kyoto, 606-8507, Japan|Niigata Cancer Ctr Hospital; Breast Surgery, Niigata, 951-8566, Japan|National Hospital Organization Osaka National Hospital; Breast Surgery, Osaka, 540-0006, Japan|Osaka International Cancer Institute; Breast and Endocrine Surgery, Osaka, 541-8567, Japan|Saitama Medical University International Medical Center; Breast Oncology, Saitama, 350-1298, Japan|Saitama Cancer Center, Breast Oncology, Saitama, 362-0806, Japan|Shizuoka Cancer Center; Breast Surgery, Shizuoka, 411-8777, Japan|Shizuoka General Hospital; Breast Surgery, Shizuoka, 420-8527, Japan|Jichi Medical School ; Surgery, Tochigi, 329-0498, Japan|National Cancer Center Hospital; Medical Oncology, Tokyo, 104-0045, Japan|Tokyo Metropolitan; Komagome Hospital, Surgery, Tokyo, 113-8677, Japan|The Cancer Inst. Hosp. of JFCR; Breast Oncology Center, Tokyo, 135-8550, Japan|Tokyo Medical Uni. Hospital; Breast Oncology, Tokyo, 160-0023, Japan|Seoul National University Bundang Hospital, Seongnam-si, 463-707, Korea, Republic of|Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology, Seoul, 03080, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, 120-752, Korea, Republic of|Kyunghee University Hospital; Endocrinology, Seoul, 130-702, Korea, Republic of|Samsung Medical Centre; Division of Hematology/Oncology, Seoul, 135-710, Korea, Republic of|Korea University Anam Hospital; Oncology Haemotology, Seoul, 136-705, Korea, Republic of|Centro Estatal de Oncología de Campeche, Campehe, Campeche, 24096, Mexico|Fundacion Rodolfo Padilla Padilla A.C., León, Guanajuato, 37000, Mexico|Núcleo de Especialidades Oncológicas, Guadalajara, Jalisco, 44670, Mexico|Hospital Angeles Metropolitano; Room 220, Mexico City, Mexico CITY (federal District), 06760, Mexico|Hospital General de México; Unidad de Oncologia, Mexico DF, Mexico CITY (federal District), 06726, Mexico|Centro Universitario Contra El Cancer, Monterrey, Nuevo LEON, 64020, Mexico|Centro de Diagnóstico y Tratamiento Integral de Mama, Hospital San José Tec de Monterrey, Montrrey, Nuevo LEON, 64710, Mexico|Oaxaca Site Management Organization, Oaxaca de Juárez, Oaxaca, 68000, Mexico|Cancerologia de Queretaro; Oncologia, Queretaro, Queretaro, Queretaro, 76090, Mexico|Médicos Especialistas en Cáncer SC, Aguascalientes, 20230, Mexico|Centro Estatal De Cancerologia De Durango; Oncology, Durango, 34000, Mexico|Centro Regional de Enfermedades Oncológicas, S.A., San Luis Potosi, 78218, Mexico|Medisch Centrum Alkmaar, Alkmaar, 1815 JD, Netherlands|Amphia ziekenhuis, locatie langendijk, Breda, 4818 CK, Netherlands|Reinier de Graaf Gasthuis, Delft, 2625 AD, Netherlands|Academish Ziekenhuis Maastricht (Azm); Inwendige Geneeskunde, Maastricht, 6229 HX, Netherlands|Isala Klinieken, Zwolle, 8011 JW, Netherlands|Waikato Hospital; Dept of Medical Oncology, Hamilton, 3240, New Zealand|Palmerston North Hospital; Regional Cancer Treatment Service, Palmerston North, 4442, New Zealand|The Panama Clinic, Panama, 0832, Panama|Centro Oncologico America, Panama, 0834-02723, Panama|Instituto Nacional de Enfermedades Neoplasicas, Lima, 15038, Peru|Clinica Anglo Americana - Centro de Investigacion Oncologia CAA, Lima, L27, Peru|Clinica El Golf, San Isidro, L27 Lima, Peru|Clinica Peruana Americana, Trujillo, 13011, Peru|University Of Santo Tomas; Oncology; Benavides Cancer Institute, Manila, 1008, Philippines|Rizal Medical Center, Pasig City, 1605, Philippines|Veterans Memorial Medical Ctr; Cancer Research Centre, Quezon City, 1101, Philippines|Bialostockie Ctr Onkologii; Oddzial Chemioterapii Dziennej, Bialystok, 15-027, Poland|Centrum Onkologii;Im. Franciszka Lukaszczyka;Onkologii, Bydgoszcz, 85-796, Poland|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, 80-214, Poland|Opolskie Centrum Onkologii;Oddzial Onkologii Klinicznej, Opole, 45-061, Poland|Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr, Warszawa, 02-781, Poland|NZOZ Mazowiecki Szpital Onkologiczny Uczelni Warszawskiej im. M. Sk?odowskiej-Curie, Wieliszew, 05-135, Poland|Emergency University Bucharest Hospital; Oncology Department, Bucharest, 050098, Romania|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, 400015, Romania|Oncology Inst. Cluj-Napoca; Cancer Dept, Cluj-Napoca, 400015, Romania|Euroclinic Center of Oncology SRL, Iasi, 700106, Romania|S.I. Russian Oncological Research Center n.a. N.N. Blokhin, Moscow, Moskovskaja Oblast, 115478, Russian Federation|State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary, Pyatigorsk, Stavropol, 357502, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Tatarstan, 420029, Russian Federation|SBI of Healthcare Samara Regional Clinical Oncology Dispensary, Samara, 443031, Russian Federation|SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary, Stavropol, 355045, Russian Federation|Tula Regional Oncology Dispensary, Tula, 300053, Russian Federation|Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia|National Hospital; Oncotherapy Dept, Bloemfontein, 9301, South Africa|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Johannesburg, 2193, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, 0002, South Africa|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, 03203, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, 08916, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, 8208, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Sant Andreu de La Barca, Barcelona, 08740, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, 39008, Spain|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon de La Plana, Castellon, 12002, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, 14004, Spain|IInstituto Oncologico de San Sebastian, Oncologikoa; Servicio de Oncologia, San Sebastian, Guipuzcoa, 20014, Spain|Hospital de Donostia; Servicio de Oncologia Medica, San Sebastian, Guipuzcoa, 20080, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, 07014, Spain|Hospital Son Llatzer; Servicio de Oncologia, Palma de Mallorca, Islas Baleares, 07198, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, 15706, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, 38320, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, 08003, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, 08036, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona, 08041, Spain|Hospital Duran i Reynals; Oncologia, Barcelona, 08907, Spain|Hospital Juan Ramon Jimenez;Servicio de Oncologia, Huelva, 21005, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, 23007, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, 15006, Spain|Centro Oncológico Gallego José Antonio Quiroga y Piñeiro, Servicio de Oncologia, La Coruña, 15009, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia, Lerida, 25198, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, 28009, Spain|Centro Oncologico MD Anderson Internacional; Servicio de Oncologia, Madrid, 28033, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, 28034, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, 28041, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, 28050, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, 29010, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia, Murcia, 30008, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, 37007, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, 41009, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, 41013, Spain|Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia, Sevilla, 41014, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia, Toledo, 45004, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, 46009, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, 46010, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, 46015, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, 46026, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, 50009, Spain|Sahlgrenska Universitetssjukhuset; Onkology, Gothenburg, 41 343, Sweden|Uni Hospital Linkoeping; Dept. of Oncology, Linköping, 58185, Sweden|Karolinska University Hospital; Department of General Oncology, Stockholm, 11883, Sweden|Norrlands Universitetssjukhus, Umeå, Cancercentrum; Dept of Oncology, Umea, 90185, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, 751 85, Sweden|Universitaetsspital Basel; Onkologie, Basel, 4031, Switzerland|Hôpitaux Universit. de Genève Gynécologique - Oncologie; Gynécologie, Genève 14, 1211, Switzerland|Luzerner Kantonsspital; Medizinische Onkologie, Luzern, 6004, Switzerland|Kantonsspital St. Gallen; Onkologie/Hämatologie, St. Gallen, 9007, Switzerland|Brust-Zentrum Zürich AG Seefeldstrasse 214 Zürich, Zürich, 8008, Switzerland|Changhua Christian Hospital; Dept of Surgery, Changhua, 500, Taiwan|Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery, Kaohsiung, 807, Taiwan|Taichung Veterans General Hospital; Dept of Surgery, Taichung, 407, Taiwan|National Cheng Kung Uni Hospital; Surgery, Tainan, 704, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, 00112, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, 100, Taiwan|Tri-Service General Hospital, Division of General Surgery, Taipei, 114, Taiwan|Chiang Rai Prachanukraw Hospital; Department of Pediatrics, Faculty of Medicine, Chiang Rai, 57000, Thailand|Lopburi Cancer Hospital; Chemotherpy Unit; Chemotherapy, Lopburi, 15000, Thailand|Buddhachinaraj Phitsanulok Hospital; Chemotherapy Unit ; Department of Medicine, Phitsanuok, 65000, Thailand|Songklanagarind Hospital; Department of Surgery, Songkla, 90110, Thailand|Surat Thani Hospital, Surat Thani, 84000, Thailand|Cherkassy Regional Oncological Hospital, Cherkassy, 18009, Ukraine|State Medical Academy; Oncology, Dnipropetrovsk, 43102, Ukraine|Ivano-Frankivsk Regional Oncology Center, Ivano-Frankivsk, 76018, Ukraine|Kyiv City Clinical Oncological Center, Day Hospital Department for Oncological patients, Kiev, 03115, Ukraine|Volyn Regional Oncology Dispensary, Lutsk, 43018, Ukraine|Lvov State Regional Oncology Medical & Diagnostic Center, Lvov, 79031, Ukraine|Ternopil State Medical Academy, Ternopil, 46023, Ukraine|Royal Berkshire Hospital; Berkshire Cancer Centre, Berkshire, RG1 5AN, United Kingdom|Velindre Cancer Centre; Oncology Dept, Cardiff, CF14 2TL, United Kingdom|Cheltenham General Hospital; Gloucestershire Oncology Centre, Cheltenham, GL53 7AN, United Kingdom|Colchester General Hospital, Colchester, Essex, CO4 5JL, United Kingdom|Royal Cornwall Hospital; Dept of Clinical Oncology, Cornwall, TR1 3LQ, United Kingdom|University Hospital coventry; Oncology Department, Coventry, CV2 2DX, United Kingdom|Western General Hospital; Edinburgh Breast Unit, Edinburgh, EH4 2XU, United Kingdom|Royal Devon & Exeter Hospital; Oncology Centre, Exeter, EX2 5DW, United Kingdom|Ipswich Hospital; Oncology Pharmacy, Ipswich, IP4 5PD, United Kingdom|St James Uni Hospital; Icrf Cancer Medicine Research Unit, Leeds, LS9 7TF, United Kingdom|St. Bartholomew'S Hospital; Dept of Medical Oncology, London, EC1A 7BE, United Kingdom|UCL Hospital NHS Trust, London, NW1 2PG, United Kingdom|Royal Marsden Hospital; Dept of Med-Onc, London, SW3 6JJ, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, M20 4QL, United Kingdom|Mount Vernon Hospital; Centre For Cancer Treatment, Northwood, HA6 2RN, United Kingdom|Nottingham City Hospital; Oncology, Nottingham, NG5 1PB, United Kingdom|Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, OX3 7LJ, United Kingdom|Peterborough City Hospital, Edith Cavell Campus; Oncology Department, Peterborough, PE3 9GZ, United Kingdom|Queen Alexandra Hospital; Haematology and Oncology Centre, Portsmouth, PO6 3LY, United Kingdom|Royal Preston Hosp; Rosemere Cancer Ctr, Preston, PR2 9HT, United Kingdom|Weston Park Hospital; Cancer Clinical Trials Centre, Sheffield, S10 2SJ, United Kingdom|Uni Hospital of North Staffordshire; Staffordshire Oncology Centre, Stoke-on-Trent, ST4 6QG, United Kingdom|Royal Marsden Hosp NHS Fnd; Medicine - Breast Unit, Sutton, SM2 5PT, United Kingdom|The Clatterbridge Cancer Ctr For Oncolgy, Wirral, CH63 4JY, United Kingdom|New Cross Hospital; Deansley Centre, Wolverhampton, WV10 0QP, United Kingdom",
